DMKJ
David M. Knott Jr Portfolio holdings
AUM
$221M
1-Year Return
22.52%
This Quarter Return
-12.56%
1 Year Return
+22.52%
3 Year Return
+148.91%
5 Year Return
–
10 Year Return
–
AUM
$212M
AUM Growth
-$64.6M
(-23%)
Cap. Flow
-$15.8M
Cap. Flow
% of AUM
-7.47%
Top 10 Holdings %
Top 10 Hldgs %
72.97%
Holding
103
New
14
Increased
10
Reduced
14
Closed
19
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$1.74M |
| 2 |
Myriad Genetics
MYGN
|
$1.42M |
| 3 |
Cogent Biosciences
COGT
|
$1.28M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$1.27M |
| 5 |
Bristol-Myers Squibb
BMY
|
$1.16M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$4.53M |
| 2 |
Calumet Specialty Products
CLMT
|
$4.49M |
| 3 |
Invesco AAA CLO Floating Rate Note ETF
ICLO
|
$3.34M |
| 4 |
Janus Henderson AAA CLO ETF
JAAA
|
$1.96M |
| 5 |
Viking Therapeutics
VKTX
|
$1.57M |
Sector Composition
| 1 | Healthcare | 33.25% |
| 2 | Materials | 20.41% |
| 3 | Financials | 19.12% |
| 4 | Communication Services | 8.29% |
| 5 | Industrials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Regeneron Pharmaceuticals
REGN
$60.8B
| $1.27M | 0.6% |
+2,000
| New | +$1.27M |
|
|
27
Bristol-Myers Squibb
BMY
$96B
| $1.16M | 0.55% |
+19,000
| New | +$1.16M |
|
28
Collegium Pharmaceutical
COLL
$1.21B
| $1.15M | 0.54% |
38,473
+5,546
| +17% | +$166K |
|
29
SPDR S&P Biotech ETF
XBI
$5.39B
| $1.11M | 0.52% |
13,643
+3,643
| +36% | +$295K |
|
30
Ryman Hospitality Properties
RHP
$6.35B
| $1.1M | 0.52% |
12,000
| – | – |
|
31
AbbVie
ABBV
$375B
| $1.06M | 0.5% |
5,037
| – | – |
|
32
Arcellx
ACLX
$4.03B
| $984K | 0.46% |
+15,000
| New | +$984K |
|
33
Kimberly-Clark
KMB
$43.1B
| $853K | 0.4% |
6,000
| – | – |
|
34
MeiraGTx Holdings
MGTX
$619M
| $848K | 0.4% |
125,010
+29,930
| +31% | +$203K |
|
35
AtriCure
ATRC
$1.76B
| $794K | 0.37% |
+24,620
| New | +$794K |
|
|
MREO
36
Mereo BioPharma
MREO
$281M
| $719K | 0.34% |
319,337
-11,663
| -4% | -$26.2K |
|
|
TECX
37
Tectonic Therapeutic, Inc. Common Stock
TECX
$314M
| $708K | 0.33% |
+40,000
| New | +$708K |
|
38
DuPont de Nemours
DD
$32.6B
| $703K | 0.33% |
9,418
-512
| -5% | -$38.2K |
|
39
Corteva
CTVA
$49.1B
| $695K | 0.33% |
11,051
-512
| -4% | -$32.2K |
|
|
ATYR
40
aTyr Pharma
ATYR
$550M
| $675K | 0.32% |
223,407
-84,726
| -27% | -$256K |
|
|
AUTL
41
Autolus Therapeutics
AUTL
$389M
| $651K | 0.31% |
+420,000
| New | +$651K |
|
42
Mondelez International
MDLZ
$79.9B
| $611K | 0.29% |
9,000
| – | – |
|
|
INZY
43
DELISTED
Inozyme Pharma
INZY
| $606K | 0.29% |
666,204
-28,796
| -4% | -$26.2K |
|
44
Microsoft
MSFT
$3.68T
| $601K | 0.28% |
1,600
| – | – |
|
45
Apple
AAPL
$3.56T
| $554K | 0.26% |
2,494
| – | – |
|
46
IBM
IBM
$232B
| $533K | 0.25% |
2,142
| – | – |
|
47
Xenon Pharmaceuticals
XENE
$3.02B
| $532K | 0.25% |
15,866
-5,000
| -24% | -$168K |
|
48
Canadian Natural Resources
CNQ
$63.2B
| $517K | 0.24% |
16,800
| – | – |
|
49
Solid Biosciences
SLDB
$428M
| $488K | 0.23% |
+132,000
| New | +$488K |
|
|
CYBN
50
Cybin
CYBN
$159M
| $424K | 0.2% |
66,880
+6,434
| +11% | +$40.8K |
|